Gflas Life Sciences, Inc.

Seoul National University

Jung Hak Lim

Dong Wook Kim

Sunghwa Choe

Jongjin Park

Sungyong In

Aiden Y Park

Mi Jin Park

Youngdong Yoo

A pharmaceutical composition for treating cancer, containing a crRNA and an endonuclease as active ingredients is disclosed. The composition can be customized according to the needs of patients or cell types by specifically treating cancer cells on the basis of specific binding properties of DNA and RNA. The nuclease activity of a CRISPR PLUS system, containing both an endonuclease and an exonuclease can be activated by means of the binding between crRNA and a gene specifically found in cancer cells. Therefore, the cancer treatment effect of the composition is more specific than that of other anti-cancer agents that have been developed up till now.

Pharmaceutical composition for treating cancer, containing guide RNA and endonuclease as active ingredients

Enhanced, specific nucleic acid targeting complexes comprising endo and exonuclease activity, and related methods that allow both targeted degradation of specific and/or non-specific nucleic acids in vivo and specific temporal regulation of nuclease activity to prevent off-target activity are disclosed herein. Through practice of the disclosure, nucleic acids, and cells harboring them, such as cancer cells or pathogens, are selectively degraded in vivo.

Sequence-specific in vivo cell targeting

Growing community of inventors

Seoul, South Korea

Jung Hak Lim